López-Jiménez Nuria, García-Sánchez Fiamma, Pailos Rafael Hernández, Rodrigo-Álvaro Valentin, Pascual-Pedreño Ana, Moreno-Cid María, Hernández-Martínez Antonio, Molina-Alarcón Milagros
Department of Obstetrics and Gynecology, La Mancha Centro Hospital, 13600 Alcazar de San Juan, Spain.
Department of Nursing, Physiotherapy and Occupational Therapy, Faculty of Nursing, University of Castilla-La Mancha IDINE, Camilo José Cela, 14, 13071 Ciudad Real, Spain.
J Clin Med. 2022 Apr 15;11(8):2217. doi: 10.3390/jcm11082217.
Purpose: To evaluate the effect and safety of vaginal dinoprostone in pregnant women with PROM who undergo induction of labor (IoL). Materials and Methods: Prospective observational study conducted at La Mancha Centro hospital from 1 February 2019, to 30 August 2020. Obstetric and neonatal variables of 94 pregnant women with PROM who underwent IoL with vaginal dinoprostone were analyzed, and the results were compared with 330 patients without PROM who also underwent IoL. Bivariate and multivariate analyses were performed using binary and multiple linear regression. Results: A total of 424 women were included in this study. A greater response to cervical ripening (Bishop score > 6) with PGE2 was observed in the PROM group (odds ratio (OR) 2.73, 95% confidence interval (CI) 1.50−4.99, p = 0.001), as well as a shorter total duration of IoL (mean difference (MD) 2823.37 min (min), 95% CI 1257.30−4389.43, p < 0.001). Cesarean sections were performed in 28.7% (n = 27) of patients in the PROM group vs. 34.2% (n = 113) of patients in the non-PROM group, with no significant differences (OR 0.87%, 95% CI 0.47−1.60, p = 0.652). There were no significant differences in changes in the cardiotocographic record (CTG), postpartum hemorrhage (PPH), uterine rupture, or adverse neonatal outcomes between the two groups. Conclusions: The use of vaginal dinoprostone in pregnant women undergoing IoL with PROM is safe for the mother and the fetus, shortens the total delivery time, and does not increase the risk of cesarean section compared with pregnant women undergoing IoL without PROM.
评估阴道用地诺前列酮对胎膜早破孕妇引产的有效性和安全性。材料与方法:于2019年2月1日至2020年8月30日在拉曼查中心医院进行前瞻性观察研究。分析了94例接受阴道用 地诺前列酮引产的胎膜早破孕妇的产科和新生儿变量,并将结果与330例同样接受引产但未发生胎膜早破的患者进行比较。采用二元和多元线性回归进行双变量和多变量分析。结果:本研究共纳入424名女性。胎膜早破组使用PGE2时宫颈成熟度( Bishop评分>6)的反应更强(优势比(OR)2.73,95%置信区间(CI)1.50−4.99,p = 0.001),引产总时长也更短(平均差(MD)2823.37分钟(min),95%CI 1257.30−4389.43,p < 0.001)。胎膜早破组28.7%(n = 27)的患者进行了剖宫产,非胎膜早破组为34.2%(n = 113),差异无统计学意义(OR 0.87%,95%CI 0.47−1.60,p = 0.652)。两组间胎心监护记录(CTG)变化、产后出血(PPH)、子宫破裂或不良新生儿结局均无显著差异。结论:与未发生胎膜早破的引产孕妇相比,胎膜早破引产孕妇使用阴道用 地诺前列酮对母体和胎儿均安全,可缩短总分娩时间,且不增加剖宫产风险。